Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company whose news flow centers on glaucoma, corneal disorders, and retinal diseases. The company’s updates frequently highlight its Micro-Invasive Glaucoma Surgery (MIGS) platform, long-duration intracameral implants, and bio-activated pharmaceutical therapies for chronic eye conditions.
Investors following GKOS news can expect regular announcements on financial performance, including quarterly and annual net sales results, segment trends in glaucoma and corneal health, and updates to revenue guidance ranges. These disclosures are often accompanied by conference call and webcast details, as well as supplemental materials such as quarterly summary documents.
Product and pipeline developments are another major focus of Glaukos news. Recent communications have described the commercial launch activities for iDose TR, a long-duration intracameral procedural pharmaceutical implant for glaucoma, and U.S. FDA approval of Epioxa HD / Epioxa, an incision-free, epithelium-on corneal collagen cross-linking therapy for keratoconus. The company also highlights scientific presentations and posters featuring its technologies at major ophthalmology meetings.
Corporate and operational updates appear in the news flow as well, including participation in healthcare and investor conferences and plans for a new research, development, and manufacturing facility in Huntsville, Alabama. Together, these items provide insight into Glaukos’ commercial execution, research pipeline, manufacturing expansion, and overall strategy in ophthalmic pharmaceuticals and medical technology.
For market participants, the GKOS news page offers a consolidated view of these developments, making it easier to track key milestones in glaucoma devices, corneal cross-linking therapies, and other chronic eye disease initiatives reported by the company.
Glaukos Corporation (NYSE: GKOS) announced positive results from a multi-center clinical trial assessing the iDose TR exchange procedure for patients previously treated with the implant. The trial showed that a second administration of iDose TR was safe, with no subjects experiencing over 30% endothelial cell loss over an average of 5.2 years. The company plans to include these results in its FDA New Drug Application submission in Q1 2023. Glaukos aims to improve glaucoma treatment paradigms with this innovative technology.
Glaukos Corporation (NYSE: GKOS) announced significant developments in its clinical pipeline, including the start of subject enrollment for a Phase 3 confirmatory trial of Epioxa™ for keratoconus treatment and positive Phase 2a results for GLK-301 for Dry Eye Disease. The latter demonstrates improved tear film quality and vision. Approximately 290 subjects will be randomized in the Epioxa trial, targeting completion by the end of 2023. These milestones are expected to propel advancements in Glaukos' innovative therapies for chronic eye diseases.
Glaukos Corporation (NYSE: GKOS) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:15 p.m. PT in San Francisco, CA. This event highlights Glaukos' focus on innovation in ophthalmic medical technology and pharmaceuticals, specifically targeting glaucoma and other ocular disorders. A live and archived webcast will be available on their investor relations website, providing insights into their ongoing development of novel therapies and medical devices aimed at advancing treatment standards.
Glaukos Corporation (NYSE: GKOS) announced management's participation in the Stephens Annual Investment Conference on November 16, 2022, at 2:00 p.m. CT in Nashville, TN. The event will be accessible via a live and archived webcast on their Investors section of the website. Glaukos specializes in ophthalmic medical technology and pharmaceuticals, focusing on innovative treatments for glaucoma, corneal disorders, and retinal diseases. They pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance glaucoma treatment.
Glaukos Corporation (GKOS) reported third-quarter 2022 net sales of $71.3 million, a decline of 4.6% year-over-year. The glaucoma segment generated $53.7 million, while corneal health contributed $17.5 million. Gross margin was approximately 76%, down from 79% in Q3 2021. SG&A expenses rose 6% to $47.1 million, and R&D expenses slightly increased. The net loss was $27.6 million or ($0.58) per diluted share. The company updated its 2022 net sales guidance to $278 million to $280 million. Glaukos ended the quarter with approximately $371 million in cash and equivalents.
Glaukos Corporation (NYSE: GKOS) announces its third quarter 2022 financial results will be released after market close on November 2, 2022. A conference call and webcast will follow at 1:30 p.m. PT (4:30 p.m. ET) for management to discuss the results. The company focuses on novel therapies for glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012. A replay of the call will be available on Glaukos' website post-event.
Glaukos Corporation (NYSE: GKOS) announces its participation in the American Academy of Ophthalmology (AAO) annual meeting, September 30 - October 3, 2022, in Chicago, IL. The company will showcase advancements in glaucoma and corneal health technologies. Key topics include novel intraoperative OCT use, trabecular bypass surgery efficacy, and corneal health presentations. Glaukos will exhibit at booth #4503, highlighting their commitment to innovative ophthalmic treatments. Further details and abstracts are available on the AAO website.
Glaukos Corporation (NYSE: GKOS) announced that both iDose TR Phase 3 pivotal trials achieved their primary efficacy endpoints. The trials showed that 93% of slow-release iDose TR subjects remained well-controlled on the same or fewer IOP-lowering medications at 12 months, with 81% completely medication-free. The treatment demonstrated excellent tolerability, with 98% continuing after 12 months, and a favorable safety profile. Glaukos is preparing for an NDA submission to the FDA, with a decision expected by the end of 2023.
Glaukos Corporation (NYSE: GKOS) has announced a major milestone with over one million implantations of its iStent technology worldwide. This achievement underscores Glaukos' pioneering role in Micro-Invasive Glaucoma Surgery (MIGS), reflecting more than 20 years of innovation and investment in glaucoma treatment options.
Industry experts emphasize that iStent has significantly improved patient outcomes and allowed for earlier interventions in glaucoma treatment. Glaukos continues to invest over 30% of its revenue into research and development to enhance its product offerings.
On August 24, iVeena Delivery Systems entered a strategic licensing agreement with Glaukos Corporation (GKOS) for IVMED-80, an eye drop designated for keratoconus. Glaukos paid $10 million upfront and will cover all development costs. The deal includes potential milestone payments and royalties for iVeena. iVeena is also working on IVMED-85, aimed at pediatric myopia, with plans for a clinical trial in early 2023.